Mechanistic differences between phenotypes of chronic lung allograft dysfunction after lung transplantation.

Authors:
Suwara MI; Vanaudenaerde BM; Verleden SE; Vos R; Green NJ and 8 more

Journal:
Transpl Int

Publication Year: 2014

DOI:
10.1111/tri.12341

PMCID:
PMC4282071

PMID:
24750386

View on PubMed View on PMC View Publisher
Journal Information

Full Title: Transpl Int

Abbreviation: Transpl Int

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Transplantation

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
A Novel Case of CMV Resistance to Valganciclovir and Maribavir in a Renal Transplant Patient.
Pearce H; Montgomery EK; Sheerin N and 1 more (2024) - Transparency Score: 2/6
Aortobifemoral Bypass in Kidney Transplant Candidates: A Ten-Year Experience.
Bonnin P; Kuntz S; Caillard S and 2 more (2024) - Transparency Score: 2/6
Beyond the First Year: Epidemiology and Management of Late-Onset Opportunistic Infections After Kid…
Esnault V; Hoisnard L; Peiffer B and 10 more (2024) - Transparency Score: 2/6
Clinical Pig Heart Xenotransplantation-Where Do We Go From Here?
Cooper DKC; Cozzi E. (2024) - Transparency Score: 2/6
CMV Infection and Lymphopenia: Warning Markers of <i>Pneumocystis</i> Pneumonia in Kidney Transplan…
Eberl I; Binquet C; Guilloteau A and 5 more (2024) - Transparency Score: 2/6
View All Papers from This Journal
Transparency Score
2/6
0.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Conflicts of interest The authors have declare no conflicts of interest."

Evidence found in paper:

"Funding Grants: GMV is holder of the GSK (Belgium) chair in respiratory pharmacology at the KULeuven and is supported by the university (OT OT10/050) and National Research Foundation Flanders (FWO): G.0723.10, G.0679.12, and G.0705.12. BMV is a senior research fellow and holder of a long-term traveling grant of the FWO. AJF is supported by Biotechnology and Biological Sciences Research Council. RV is supported by the Research Foundation Flanders (FWO) (KAN2014 1.5.139.14) and Klinisch Onderzoeksfonds (KOF) KULeuven. SEV is supported by the Onderzoeksfonds KULeuven."

Protocol Registration
Open Access
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025